B. E. Johnson

649 total citations
17 papers, 534 citations indexed

About

B. E. Johnson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, B. E. Johnson has authored 17 papers receiving a total of 534 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 13 papers in Oncology and 5 papers in Cancer Research. Recurrent topics in B. E. Johnson's work include Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (8 papers) and Cancer Genomics and Diagnostics (5 papers). B. E. Johnson is often cited by papers focused on Lung Cancer Treatments and Mutations (14 papers), Lung Cancer Research Studies (8 papers) and Cancer Genomics and Diagnostics (5 papers). B. E. Johnson collaborates with scholars based in United States. B. E. Johnson's co-authors include V.A. Miller, Paula G. O’Connor, C. Soh, Fairooz F. Kabbinavar, Mark G. Kris, Giuseppe Giaccone, William Pao, A. John Iafrate, Fadlo R. Khuri and Charles M. Rudin and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cold Spring Harbor Symposia on Quantitative Biology.

In The Last Decade

B. E. Johnson

17 papers receiving 509 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
B. E. Johnson United States 12 388 359 209 101 36 17 534
U. Brennscheidt Germany 13 321 0.8× 420 1.2× 206 1.0× 44 0.4× 30 0.8× 30 613
Janusz Milanowski Poland 4 636 1.6× 603 1.7× 174 0.8× 68 0.7× 32 0.9× 11 722
M.P. López-Cabrerizo Spain 7 414 1.1× 404 1.1× 144 0.7× 105 1.0× 72 2.0× 8 577
V. Gorbounova Russia 3 397 1.0× 359 1.0× 124 0.6× 95 0.9× 46 1.3× 7 516
H. Doubre France 12 524 1.4× 372 1.0× 113 0.5× 81 0.8× 62 1.7× 33 629
Henk Mallo Netherlands 12 183 0.5× 236 0.7× 167 0.8× 65 0.6× 19 0.5× 24 447
Antonella Flacco Italy 9 482 1.2× 381 1.1× 269 1.3× 179 1.8× 67 1.9× 13 623
Aristea Kalikaki Greece 7 374 1.0× 369 1.0× 222 1.1× 184 1.8× 94 2.6× 9 589
Kevin Jao Canada 10 337 0.9× 293 0.8× 145 0.7× 142 1.4× 24 0.7× 23 476
Antonio Russo Italy 8 270 0.7× 296 0.8× 114 0.5× 155 1.5× 33 0.9× 14 428

Countries citing papers authored by B. E. Johnson

Since Specialization
Citations

This map shows the geographic impact of B. E. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B. E. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B. E. Johnson more than expected).

Fields of papers citing papers by B. E. Johnson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B. E. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B. E. Johnson. The network helps show where B. E. Johnson may publish in the future.

Co-authorship network of co-authors of B. E. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of B. E. Johnson. A scholar is included among the top collaborators of B. E. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B. E. Johnson. B. E. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Lungren, Matthew P., et al.. (2014). Global Health Imaging Curriculum in Radiology Residency Programs: The Fundamentals. Journal of the American College of Radiology. 11(10). 968–973. 15 indexed citations
2.
Kris, Mark G., B. E. Johnson, D J Kwiatkowski, et al.. (2011). Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).. Journal of Clinical Oncology. 29(15_suppl). CRA7506–CRA7506. 176 indexed citations
3.
4.
Leighl, N. B., Jean‐Charles Soria, Jaafar Bennouna, et al.. (2010). Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 28(15_suppl). 7524–7524. 15 indexed citations
5.
6.
Johnson, B. E., Andy Ryan, John V. Heymach, et al.. (2010). Tumor biomarker analyses from the phase III ZODIAC study of docetaxel (D) plus or minus vandetanib (VAN) in second-line advanced NSCLC.. Journal of Clinical Oncology. 28(15_suppl). 7516–7516. 7 indexed citations
7.
Soria, J.C., Jaafar Bennouna, Natasha B. Leighl, et al.. (2009). 9174 Phase II study of everolimus plus erlotinib in previously treated patients with advanced non-small cell lung cancer (NSCLC). European Journal of Cancer Supplements. 7(2). 558–559. 2 indexed citations
8.
Rabin, Michael S., et al.. (2008). Rates of central nervous system progression in non-small cell lung cancer patients treated with EGFR-TKI’s vs. chemotherapy. Journal of Clinical Oncology. 26(15_suppl). 8059–8059. 1 indexed citations
9.
Jackman, D. M., Lecia V. Sequist, Leigh‐Anne Cioffredi, et al.. (2008). Impact of EGFR and KRAS genotype on outcomes in a clinical trial registry of NSCLC patients initially treated with erlotinib or gefitinib. Journal of Clinical Oncology. 26(15_suppl). 8035–8035. 11 indexed citations
10.
11.
Johnson, B. E., Howard West, Robert O. Kerr, et al.. (2005). Preliminary phase II safety evaluation of ZD6474, in combination with carboplatin and paclitaxel, as 1st-line treatment in patients with NSCLC. Journal of Clinical Oncology. 23(16_suppl). 7102–7102. 40 indexed citations
12.
Heymach, John V., B. E. Johnson, Jacqui Rowbottom, et al.. (2005). A randomized, placebo-controlled phase II trial of ZD6474 plus docetaxel, in patients with NSCLC. Journal of Clinical Oncology. 23(16_suppl). 3023–3023. 36 indexed citations
13.
Kris, Mark G., V.A. Miller, D. Carbone, et al.. (2005). O-109 Phase II trial of erlotinib in patients with bronchioloalveolarcarcinoma. Lung Cancer. 49. S38–S39. 7 indexed citations
14.
Johnson, B. E.. (2003). Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer: The End of the Beginning. JNCI Journal of the National Cancer Institute. 95(19). 1422–1424. 13 indexed citations
15.
Bepler, Gerold, Kwun M. Fong, B. E. Johnson, et al.. (1998). Association of chromosome 11 locus D11S12 with histology, stage, and metastases in lung cancer.. PubMed. 22(1). 14–9. 20 indexed citations
16.
Shaw, Gail L., Adi F. Gazdar, Ruby Phelps, et al.. (1993). Individualized chemotherapy for patients with non-small cell lung cancer determined by prospective identification of neuroendocrine markers and in vitro drug sensitivity testing.. PubMed. 53(21). 5181–7. 37 indexed citations
17.
Minna, J D, J.F. Battey, Burke J. Brooks, et al.. (1986). Molecular Genetic Analysis Reveals Chromosomal Deletion, Gene Amplification, and Autocrine Growth Factor Production in the Pathogenesis of Human Lung Cancer. Cold Spring Harbor Symposia on Quantitative Biology. 51(0). 843–853. 33 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by U. Brennscheidt Breakdown of academic impact, for papers by Janusz Milanowski Breakdown of academic impact, for papers by M.P. López-Cabrerizo Breakdown of academic impact, for papers by V. Gorbounova Breakdown of academic impact, for papers by H. Doubre Breakdown of academic impact, for papers by Henk Mallo Breakdown of academic impact, for papers by Antonella Flacco Breakdown of academic impact, for papers by Aristea Kalikaki Breakdown of academic impact, for papers by Kevin Jao Breakdown of academic impact, for papers by Antonio Russo
Rankless by CCL
2026